DelMar Pharmaceuticals to sell $7 million of units through public sale

Maxim, Roth Capital are bookrunners; National Securities is co-manager

By Devika Patel

Knoxville, Tenn., May 7– DelMar Pharmaceuticals, Inc. will now raise $7 million in its public offering of units with a 45-day greenshoe, according to a Form S-1/A filed Thursday with the Securities and Exchange Commission. The company has registered up to $8.05 million of stock for the sale, which was announced as a $10 million deal on April 10.

The company will sell units of common shares and warrants.

Maxim Group LLC and Roth Capital Partners are the bookrunners. National Securities Corp. is the co-manager.

Proceeds will be used for research and drug development, working capital and general corporate purposes.

The drug developer is based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.